Daily Archives: 26/05/2026
VERVE-102
VERVE-102 is an investigational in vivo base-editing gene therapy developed by Verve Therapeutics (with Eli Lilly involved via acquisition/collaboration) that aims to provide a one-time treatment for high cholesterol by permanently inactivating the PCSK9 gene in the liver. Key Mechanism It delivers an adenine base editor (ABE) mRNA and a guide RNA (gRNA) targeting PCSK9 […]
deemagclinic
